Recently, transcriptomic data from nearly 20,000 tumors revealed that patients bearing a localized treatment-naïve primary prostate cancer with low AR-activity (AR-A; based on a signature of nine canonical AR transcriptional targets) experience a shorter time to recurrence34. Here, AR is linked to prostate carcinoma.